[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100548125":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":23,"locations":22,"responsibleParty":29,"collaborators":32,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":40,"acronym":22,"eligibilityCriteria":41,"healthyVolunteers":38,"sex":42,"minAge":43,"maxAge":22,"enrollmentInfo":44,"targetDuration":22,"studyType":47,"phases":48,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":57,"whyStopped":22,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":22},{"fullName":5,"class":6},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Cadonilimab combined with chemotherapy","EXPERIMENTAL","All subjects in the group will be treated with Cadonilimab plus gemcitabine \u002F vinorelbine \u002F pemetrexed once every three weeks.",[13],"Drug: Cadonilimab Combined with chemotherapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Cadonilimab Combined with chemotherapy","Cadonilimab (15mg\u002Fkg, intravenous drip, D1) + gemcitabine (1250mg\u002Fm2, intravenous drip, D1\u002FD8) or vinorelbine (30mg, oral, tiw, D1\u002FD3\u002FD5) or pemetrexed (500mg\u002Fm2, intravenous drip, D1), every 3 weeks.",[9],[21],"AK104",null,[24],{"name":25,"role":26,"phone":27,"phoneExt":22,"email":28},"Jie Wang","CONTACT","13910704669","zlhuxi@163.com",{"type":30,"investigatorFullName":25,"investigatorTitle":31,"investigatorAffiliation":5,"oldNameTitle":22,"oldOrganization":22},"PRINCIPAL_INVESTIGATOR","Chief physician",[33],{"name":34,"class":35},"Akesobio","INDUSTRY","100548125","phase-2-study-of-cadonilimab-combined-with-chemotherapy-in-recurrent--refractory-pleural-mesothelioma-100548125",false,"NCT06416930","Study of Cadonilimab Combined With Chemotherapy in Recurrent \u002F Refractory Pleural Mesothelioma","Inclusion Criteria:\n\n1. Histologically confirmed advanced or metastatic pleural mesothelioma;\n2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n3. Participants must have previously failed to receive platinum-containing chemotherapy with or without bevacizumab, and have received at most two-line systemic therapy.\n4. Measurable disease as per mRECIST v1.1 for assessment of response in malignant pleural mesothelioma.\n5. Adequate haematological, renal and liver function.\n\nExclusion Criteria:\n\n1. Primary mesothelioma of peritoneum, pericardium and testes\n2. Active, untreated central nervous system (CNS) metastasis.\n3. Use of Chinese herbal medicine or immunomodulatory agents with anti-tumor indications within 14 days prior to the first dose of study treatment.\n4. Known active autoimmune diseases.\n5. Presence of other uncontrolled serious medical conditions.","ALL","18 Years",{"count":45,"type":46},59,"ESTIMATED","INTERVENTIONAL",[49],"PHASE2","This is a multicenter, single-arm, phase II clinical study to evaluate the safety and efficacy of Cadonilimab combined with gemcitabine, or vinorelbine, or pemetrexed in the treatment of patients with recurrent \u002F refractory pleural mesothelioma.",[52],"Pleural Mesothelioma",[54,55,56],"Cadonilimab","pleural mesothelioma","Bispecific Antibody","NOT_YET_RECRUITING","2024-05-12",{"date":60,"type":61},"2024-05-16","ACTUAL",{"date":63,"type":46},"2024-06-20",{"date":65,"type":46},"2029-06-20",{"name":5,"class":6}]